Skip to main content

Table 3 Validation studies for association of DEPDC5 with the risk of HCC development among chronic hepatitis patients

From: Main insights of genome wide association studies into HCV-related HCC

Study/year Ethnicity Cases/controls P value OR(95%CI)
Motomura 2012 [21] Japanese Cohort of 96 HCC hepatectomy patients. 0.47
Al-Qahtani 2014 [22] Saudi 151 cirrhotic patients + HCC patients/450 Chronic HCV patients. 0.038 1.353 (1.017–1.80)
Ma 2014 [23] Chinese 308 HBV-HCC/373 HBV carriers and 111 cirrhotic patients HCC VS HBV 0.001
HCC VS cirrhosis
0.009
HCC VS HBV carriers 1.549 (1.207–1.988)
HCC VS cirrhosis 1.837 (1.168–2.902 )
Hai 2014 [17] Japanese 142 HCV-HCC/575 HCV non-HCC patients 0.51
Burza 2016 [14] Italy, Switzerland, Germany 192 LC-HCC/199 LC 0.15
Liu 2019 [24] Chinese 308 HBV-HCC patients/217 chronic HBV, 258 cirrhotic, and 506 healthy controls. HCC VS healthy controls = 0.015
HCC VS CHB = 0.02
HCC VS LC = 0.004
HCC VS healthy controls
2.008 (1.145, 3.520)
HCC VS CHB
2.241 (1.226–4.461)
HCC VS LC
2.706 ( 1.371- 5.340)
  1. HCC hepatocellular carcinoma, LC liver cirrhosis, HCV hepatitis C virus, HBV hepatitis B virus, CHB chronic hepatitis B